UBS Group’s Immune Design Corp. IMDZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-4,765
| Closed | -$28K | – | 8559 |
|
|
2019
Q1 | $28K | Sell |
4,765
-20,335
| -81% | -$69.3K | ﹤0.01% | 6026 |
|
|
2018
Q4 | $33K | Buy |
25,100
+13,989
| +126% | +$24.3K | ﹤0.01% | 6432 |
|
|
2018
Q3 | $39K | Buy |
11,111
+5,248
| +90% | +$19.7K | ﹤0.01% | 6365 |
|
|
2018
Q2 | $27K | Buy |
+5,863
| New | +$23.4K | ﹤0.01% | 6497 |
|
|
2018
Q1 | – | Sell |
-1,297
| Closed | -$5K | – | 8606 |
|
|
2017
Q4 | $5K | Buy |
1,297
+734
| +130% | +$4K | ﹤0.01% | 7440 |
|
|
2017
Q3 | $6K | Buy |
563
+128
| +29% | +$1.26K | ﹤0.01% | 7192 |
|
|
2017
Q2 | $4K | Sell |
435
-3
| -0.7% | -$21 | ﹤0.01% | 7266 |
|
|
2017
Q1 | $3K | Sell |
438
-5,388
| -92% | -$31.2K | ﹤0.01% | 7259 |
|
|
2016
Q4 | $32K | Buy |
+5,826
| New | +$41.2K | ﹤0.01% | 6200 |
|
|
2016
Q1 | – | Sell |
-3,301
| Closed | -$66K | – | 8873 |
|
|
2015
Q4 | $66K | Buy |
3,301
+3,046
| +1,195% | +$52.5K | ﹤0.01% | 5582 |
|
|
2015
Q3 | $3K | Buy |
+255
| New | +$4.78K | ﹤0.01% | 8031 |
|
|
2015
Q1 | – | Sell |
-832
| Closed | -$26K | – | 10203 |
|
|
2014
Q4 | $26K | Buy |
+832
| New | +$23.1K | ﹤0.01% | 7300 |
|
UBS Group's IMDZ Position: Q2 2019 in Review
UBS Group sold out of Immune Design Corp. (IMDZ) in Q2 2019, closing a stake of 4,765 shares — an estimated $28K sold.
UBS Group first reported a position in IMDZ in Q4 2014 and held it in 12 quarters. The position peaked at $66K in Q4 2015. 0 funds tracked by Wall St. Rank hold IMDZ as of Q2 2019.
- UBS Group reported no remaining Immune Design Corp. position as of Q2 2019 after selling out during the quarter.
- UBS Group sold 4,765 Immune Design Corp. shares in Q2 2019, an estimated $28K.
- UBS Group first reported a position in Immune Design Corp. in Q4 2014 and held it in 12 quarters.
- UBS Group's Immune Design Corp. position peaked at $66K in Q4 2015.
- 0 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2019.
Based on UBS Group's 13F filing for Q2 2019, filed 14 Aug 2019.